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IntroductIon
Inflammasomes are large molecular platforms that are assem-
bled in the cytoplasm in response to pathogens and danger 
signals. Faithful regulation of inflammasome activity is crucial 
to maintain efficient host defense in complex organisms. In-
flammasome activation leads to maturation and secretion of 
the proinflammatory cytokines IL-1β and IL-18, which ini-
tiate early inflammatory responses. Moreover, it causes a fast 
proinflammatory form of cell death called pyroptosis (Rathi-
nam and Fitzgerald, 2016). Uncontrolled inflammasome ac-
tivation contributes to development of neurodegenerative, 
metabolic, and autoimmune/autoinflammatory diseases as 
well as cancer (Strowig et al., 2012; Broz and Dixit, 2016).
Different sensing molecules of the family of cytoplasmic 
pattern-recognition receptors form distinct inflammasome 
complexes specialized to detect specific pathogen compo-
nents and/or danger signals (Lamkanfi and Dixit, 2012). The 
NLRP3 inflammasome is unique in the sense that it is capable 
of detecting a broad variety of danger signals. Activation of the 
NLRP3 inflammasome occurs in two steps. Priming through 
cytokine or pattern-recognition receptor signaling leads to 
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transcription and translation of NLRP3 and pro–IL-1β. Dif-
ferent stimuli, including ATP, toxins, and crystalline reagents, 
in turn trigger assembly of the inflammasome, a multimeric 
protein complex consisting of NLRP3, the adaptor protein 
apoptosis-associated speck-like protein (ASC), and pro–
caspase-1. Assembly of these components leads to autoacti-
vation of caspase-1, which cleaves pro–IL-1β and pro–IL-18 
into mature cytokines (Schroder and Tschopp, 2010; Latz et 
al., 2013; Lamkanfi and Dixit, 2014). The cleavage of gasder-
min D (GSD MD), which has been recently identified as a 
novel substrate of inflammatory caspases, leads to pyroptosis 
and secretion of IL-1β and IL-18 (He et al., 2015; Kayagaki et 
al., 2015; Shi et al., 2015).
Many mechanisms leading to assembly of the NLRP3 
inflammasome have been proposed, but their links still need 
to be characterized. Among those, efflux of K+ appears to 
be a crucial upstream event required to activate the NLRP3 
inflammasome (Pétrilli et al., 2007). But how low intracel-
lular K+ induces assembly of NLRP3 is unclear. Recently, 
it has been shown that NEK7 acts downstream of K+ efflux 
to bind NLRP3, promoting its self-oligomerization (He 
et al., 2016; Schmid-Burgk et al., 2016; Shi et al., 2016). 
Several studies also provide evidence for Ca2+ mobiliza-
tion to be important for NLRP3 inflammasome activa-
tion (Lee et al., 2012; Murakami et al., 2012; Rossol et 
al., 2012). A direct implication of intracellular Ca2+ signal-
ing was, however, recently debated (Muñoz-Planillo et al., 
2013; Katsnelson et al., 2015). It was thus rather proposed 
that release of Ca2+ from the ER to mitochondria trig-
ger mitochondrial Ca2+ overload and injury (Lee et al., 
2012; Murakami et al., 2012). Damaged mitochondria in 
turn release several factors that activate the NLRP3 in-
flammasome (Nakahira et al., 2011; Shimada et al., 2012; 
Iyer et al., 2013). Release of Ca2+ from the ER is mediated 
through inositol-1, 4, 5-trisphosphate (InsP3), a product of 
phospholipase C (PLC). Even though mechanisms leading 
to PLC activity are unknown, its involvement in NLRP3 
inflammasome activation has recently been reported (Lee 
et al., 2012; Chae et al., 2015). Although PLC-mediated 
generation of InsP3 and Ca2+ overload may trigger mito-
chondrial damage, the role of the other product of PLC 
activation, diacylglycerol (DAG), remains unexplored in 
this context. Importantly, NLRP3 was shown to directly 
bind to mitochondria-associated ER membranes (MAMs; 
Zhou et al., 2011; Yang et al., 2015). However, the fully ac-
tive NLRP3 inflammasome is cytoplasmic, suggesting that 
its maturation requires additional steps.
In this study, we show that PKD signaling emanating 
from the Golgi is required for full maturation of the NLRP3 
inflammasome. In response to NLRP3 inflammasome ac-
tivators, MAMs localize adjacent to Golgi membranes. At 
the molecular level, enhanced DAG levels at the Golgi re-
cruits and activates PKD, which subsequently phosphorylates 
NLRP3, releasing it from MAMs and resulting in assembly of 
the fully mature inflammasome in the cytosol.
resuLts
MAMs localize adjacent to the Golgi, where dAG is 
enriched upon nLrP3 inflammasome activation
A current model suggests that signaling converging into PLC 
leads to generation of InsP3, inducing InsP3 receptor (In-
sP3R)–mediated release of Ca2+ from the ER to mitochon-
dria and mitochondrial Ca2+ overload and injury (Lee et al., 
2012; Murakami et al., 2012). Damaged mitochondria in turn 
release several factors that trigger activation of the NLRP3 
inflammasome (Nakahira et al., 2011; Zhou et al., 2011; Iyer 
et al., 2013; Subramanian et al., 2013; Wang et al., 2014; Gu-
rung et al., 2015). We tested whether DAG, the other product 
of PLC activation, was involved in NLRP3 inflammasome 
activation. Using a reporter consisting of a GFP fused to the 
C1 domains of protein kinase C δ (PKCδ) that bind DAG 
(Codazzi et al., 2001), we monitored localized production of 
DAG in mouse BMDMs in response to nigericin-induced 
inflammasome activation. Although the reporter was mainly 
present in the cytosol and localized only partially to the 
Golgi in nonstimulated cells, its localization was almost ex-
clusively confined to this organelle in nigericin-stimulated 
cells, indicating that DAG production in Golgi membranes 
was enhanced. Inhibition of PLC by U71322 decreased 
Golgi localization of the reporter in nigericin-stimulated 
cells (Fig.  1 A). DAG accumulation at Golgi occurred up-
stream of inflammasome activation, as deletion of NLRP3 
did not affect it (Fig. 1 B). Mitochondria associated with ER 
membranes release effectors that have been reported to me-
diate activation of the NLRP3 inflammasome (Nakahira et 
al., 2011; Zhou et al., 2011; Iyer et al., 2013; Subramanian et 
al., 2013; Wang et al., 2014; Gurung et al., 2015). Coimmu-
nostaining with markers for mitochondria and Golgi revealed 
that mitochondria predominantly clustered around the Golgi 
apparatus in BMDMs treated with different NLRP3 inflam-
masome activators (Fig. 2 A). This observation was confirmed 
in THP-1 cells, a human monocyte cell line (Fig. 2 B). Mito-
chondrial clustering close to Golgi was not affected by dele-
tion of NLRP3 in BMDMs (Fig. 2 A).
Disruption of Golgi integrity with brefeldin A (BFA) 
markedly reduced caspase-1 cleavage, IL-1β cleavage and 
secretion, and the formation of ASC specks (in ∼63% of 
DMSO-treated and ∼15% of BFA-treated cells) upon in-
flammasome activation in BMDMs (Fig. 3, A–D). Activation 
of other inflammasomes (AIM2, NLRC4, and PYR IN in-
flammasome) did not evoke mitochondrial clustering around 
the Golgi (Fig. 2 C), suggesting that the observed organelle 
distribution is specific for NLRP3 inflammasome activation. 
These data let us to hypothesize that DAG-dependent Golgi 
signaling close to MAMs might be important in NLRP3 
inflammasome activation.
PKd activity is required for nLrP3 inflammasome activation
One of the key effectors of DAG at the Golgi is PKD (Lil-
jedahl et al., 2001; Baron and Malhotra, 2002). Indeed, PKD 
was enriched in the Golgi fraction in response to NLRP3 
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inflammasome activation, which was not affected by PKD 
inhibition (Fig. S1 A). We next tested whether PKD activity is 
required for activation of the NLRP3 inflammasome. Strik-
ingly, four different PKD inhibitors (CRT 0066101, Gö 6976, 
CID 755673, and kb NB 142–70) almost completely abol-
ished inflammasome activity in stimulated peritoneal mac-
rophages and/or BMDMs without affecting expression of 
NLRP3, pro–caspase-1, pro–IL-1β, and ASC (Fig. 4, A and B; 
and Fig. S1, B and C). As previously reported (Lee et al., 2012), 
the InsP3R antagonist 2-APB almost completely blocked in-
flammasome activation (Fig. 4, A and B; and Fig. S1 C). The 
PKC inhibitor Gö 6983, which does not inhibit PKD activity 
(Uesugi et al., 2012), had no such effect (Fig. 4, A and B; and 
Fig. S1 C). Inflammasome activation was also dramatically re-
duced upon PKD inhibition in human PBMCs (Fig. 4 C).
The PKD family consists of three members: PKD1, 
PKD2, and PKD3 (Rykx et al., 2003). To further corroborate 
the requirement of PKD activity in NLRP3 inflammasome 
activation, we generated myeloid-specific PKD1-PKD3 dou-
ble-KO (PKD1-PKD3Δmy) mice (Fig. S1 D). NLRP3 inflam-
masome activation in BMDMs isolated from PKD1-PKD3Δmy 
mice was markedly reduced as compared with cells isolated 
from floxed control mice (PKD1-PKD3fl/fl; Fig. 4, D–F). Inhi-
bition was not as prominent as in PKD inhibitor–treated cells, 
most likely because of the remaining PKD2 activity. Indeed, 
additional pharmacologic inhibition of PKD (Fig.  4, D–F) 
or siRNA-mediated knockdown of PKD2 (Fig. 4 G) abol-
ished inflammasome activity in KO cells. The development 
of the myeloid lineage was not affected in PKD1-PKD3Δmy 
mice (Fig. S1, E and F). Priming and release of other NF-κB–
dependent cytokines were not impaired in BMDMs from 
PKD1-PKD3Δmy mice (Fig. S1, D, G, and H). To further cor-
roborate that remaining PKD2 activity in KO cells was indeed 
responsible for residual inflammasome activity, we generated 
Raw-ASC macrophages lacking PKD1, PKD2, and PKD3 
(Fig. S1 I). Strikingly, caspase-1 cleavage and secretion in re-
sponse to nigericin was completely abolished in these cells as 
compared with WT cells (Fig. 4 I). Inhibition was comparable 
to the one seen in NLRP3-KO cells. As expected, caspase-1 
was undetectable in Caspase-1–KO cells. In line with previ-
ous studies (He et al., 2015; Kayagaki et al., 2015; Shi et al., 
2015), caspase-1 cleavage was partially maintained, whereas its 
secretion was abolished in GSD MD-KO cells (Fig. 4 I).
Flagellin-induced NLRC4-, dsDNA-induced AIM2-, 
and cytotoxin TcdB-induced PYR IN inflammasome activa-
tion was not affected in BMDMs upon PKD inhibition. In-
hibition of PKD upon NLRC4 inflammasome activation did 
not change autocleavage of caspase-1 (Fig. S2 A). The same 
was true for AIM2 and PYR IN inflammasome activation, of 
which formation of ASC specks was also unchanged (Fig. S2 B).
Several studies have shown that gram-negative bacteria 
(Escherichia coli) and gram-positive bacteria (Staphylococcus 
aureus) activated the NRLP3 inflammasome (Mariathasan 
et al., 2006; Sander et al., 2011). In line with these studies, 
activation of NLRP3 inflammasome-dependent cleavage of 
caspase-1 in response to both E. coli DH5α and S. aureus was 
abolished in NLRP3-KO cells (Fig. 5 A). In comparison with 
WT cells, the cleavage of caspase-1 was markedly decreased in 
PKD1-PKD3Δmy cells (Fig. 5 A).
To corroborate the role of PKD in NLRP3 inflam-
masome activation in vivo, we first treated mice with LPS 
by i.p. injection in the absence or presence of PKD inhi-
Figure 1. Activation of nLrP3 inflammasome induces dAG enrich-
ment in the Golgi. (A) Confocal fluorescence imaging of LPS-primed WT 
BMDMs ectopically expressing a GFP-tagged DAG probe pretreated with 
DMSO or 10 µM U71322 for 1 h, followed by 7.5 µM nigericin stimula-
tion for 20 min in the presence of DMSO or 10 µM U71322. Cells were 
immunostained using an antibody against giantin (a marker for Golgi). 
Nuclei were stained with DAPI. Regions of interest (ROI) are indicated by 
boxes. Bars: 10 µm; [region of interest (ROI)] 2 µm. (B) Confocal fluores-
cence imaging of LPS-primed NLRP3-KO BMDMs ectopically expressing 
a GFP-tagged DAG probe (GFP) pretreated with DMSO or 10 µM U71322 
for 1 h, followed by 7.5 µM nigericin stimulation for 20 min in presence 
of DMSO or 10 µM U71322. Cells were immunostained with an antibody 
against giantin. Nuclei were stained with DAPI. Bar, 10 µm. Data shown are 
representative of three independent experiments.
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Figure 2. Activation of nLrP3 inflammasome induces mitochondrial clustering around the Golgi. (A) Confocal fluorescence imaging of LPS-primed 
WT and NLRP3-KO BMDMs treated or not with 5 mM ATP or 15 µM nigericin for 20 min or with 500 µg/ml alum or 125 µg/ml nano-SiO2 for 6 h. Cells 
were coimmunostained using antibodies against Tom20 (a marker for mitochondria) and giantin. Nuclei were stained with DAPI. Bars, 10 µm. (B) Confocal 
fluorescence imaging of PMA-differentiated THP-1 cells treated or not with 15 µM nigericin for 20 min, 500 µg/ml alum, or 125 µg/ml nano-SiO2 for 6 h. 
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bition. LPS injection increased the serum IL-1β level in 
DMSO- treated control mice (Fig. 5 B), whereas serum IL-1β 
was almost not detectable in NLRP3-KO mice (Fig. 5 B). 
In comparison with DMSO-treated control mice, CRT 
0066101–treated mice showed dramatically reduced serum 
IL-1β levels (Fig. 5 B). We next addressed PKD-dependent 
phenotypic outcomes in mice during a bacterial challenge. 
Inhibition of PKD in mice subjected to i.p. injections of S. 
aureus led to a significantly enhanced mortality as compared 
with infected DMSO-treated control mice (Fig.  5 C). Ac-
cordingly, higher mortality was accompanied with a reduced 
body temperature (Fig. 5 D) as well as an increased bacterial 
load (Fig. 5, E and F). Similarly, PKD1-PKD3Δmy mice showed 
accelerated mortality (Fig. 5 G) and lower body temperature 
(Fig. 5 H) as compared with PKD1-PKD3fl/fl control mice. 
Our data are thus in line with previous findings in ASC- and 
IL-1β–deficient mice (Miller et al., 2007), supporting that 
PKD-mediated NLRP3-dependent IL-1 β release is an im-
portant response for efficient clearance of S. aureus.
Taking all together, these data thus corrobo-
rate an important role of PKD signaling in mediating 
NLRP3 inflammasome activity.
PKd acts downstream of mitochondrial damage and is 
required for the recruitment of Asc to nLrP3
Numerous studies suggest that mitochondrial damage is 
important for the activation of the NLRP3 inflammasome 
(Nakahira et al., 2011; Zhou et al., 2011; Iyer et al., 2013; 
Subramanian et al., 2013; Gurung et al., 2015). We thus 
tested whether PKD activity controls mitochondrial func-
tion in response to NLRP3 inflammasome activation. Ox-
ygen consumption rates (OCRs) were dramatically lower in 
nigericin-stimulated cells (Fig. S3 B) than in control-treated 
cells. In line with a previous study (Shimada et al., 2012), 
nigericin-treated cells did not respond to oligomycin, FCCP, 
and rotenone/antimycin, whereas control-treated cells re-
sponded as expected. Importantly, PKD inhibition did not 
prevent nigericin-induced mitochondrial damage (Fig. S3 
B), indicating that improved mitochondrial function did not 
account for NLRP3 inflammasome inactivity upon PKD in-
hibition. This was confirmed in NLRP3-null cells (Fig. S3, A 
and B), indicating that mitochondrial injury occurs upstream 
of PKD-mediated NLRP3 inflammasome activation. More-
over, PKD inhibition did not affect mitochondrial clustering 
close to the Golgi in response to nigericin stimulation (Fig. 
S3 C). Interestingly, 2-APB prevented mitochondrial cluster-
ing close to Golgi (Fig. S3 C), suggesting that InsP3-mediated 
signaling is required for mitochondrial clustering.
We next asked whether PKD activity was important for 
recruitment of ASC to NLRP3. Strikingly, almost no ASC 
specks were found in stimulated BMDMs and THP-1 cells 
upon PKD inhibition, whereas they were present in ∼17% 
and ∼31% of respective control cells (Fig. 6, A–D). Immuno-
blotting with cross-linked pelleted protein extracts corrobo-
rated reduced oligomerization of ASC upon PKD inhibition 
(Fig.  6  E). Stimulation of BMDMs from PKD1-PKD3fl/fl 
mice with ATP and nigericin resulted in ASC speck forma-
tion in ∼23% and ∼55% of cells, respectively. ASC speck for-
mation was reduced in cells derived from PKD1-PKD3Δmy 
mice to ∼8% and ∼25%, respectively (Fig.  6  F). Overall, 
these data indicate that PKD activity downstream of mi-
tochondrial clustering and injury is required for the re-
cruitment of ASC to NLRP3.
PKd inactivation results in retention of nLrP3 
at MAMs adjacent to Golgi
NLRP3 was shown to directly bind to MAMs (Zhou et 
al., 2011; Yang et al., 2015). We thus further tested whether 
PKD deficiency affected subcellular localization of NLRP3. 
NLRP3 was found in small foci that predominantly colo-
calized with ASC specks in ∼35% of nigericin-stimulated 
THP-1 cells. In contrast, NLRP3 staining was more diffuse 
forming larger disc-like structures in ∼70% of THP-1 cells 
upon PKD inhibition (Fig.  7, A and B). NLRP3-KO cells 
did not show any visible signal of NLRP3 immunostaining 
(Fig. 7 A). Conventional confocal microscopy revealed par-
tial colocalization of NLRP3 with the Golgi marker giantin 
in PKD-inhibited cells (Fig. 7 C). 3D-SIM superresolution 
microscopy revealed that there was very little colocalization 
with giantin, indicating that NLRP3 was very close to but 
did not directly bind to Golgi membranes (Fig. 7 D). We thus 
asked whether NLRP3 was retained at MAMs close to Golgi 
membranes. Indeed, biochemical fractionation demonstrated 
increased enrichment of NLRP3 at MAMs upon PKD inhi-
bition (Fig. 7 E). Consistent with findings in THP-1 cells, in 
stimulated PKD-inhibited BMDMs, NLRP3 was found in 
bright foci that were slightly bigger as compared with those 
in control-treated cells. Most NLRP3 localized to the Golgi 
region upon PKD inhibition, whereas it predominantly local-
ized to the cytoplasm in control-treated cells (Fig. S2, C and 
D). Consistent results were observed in stimulated BMDMs 
isolated from control and PKD1-PKD3Δmy mice (Fig. S2, E 
and F). Altogether, these data suggest that PKD activity is 
required to release NLRP3 from MAMs, allowing for ASC 
recruitment and inflammasome activation.
PKd phosphorylates nLrP3 at ser293 
to release it from MAMs
We next tested whether PKD at the Golgi interacts and phos-
phorylates NLRP3 to release it from MAMs. Ectopically 
Cells were coimmunostained with anti-Tom20 and anti-giantin antibodies. Nuclei were stained with DAPI. Bar, 10 µm. (C) Confocal fluorescence imaging 
of LPS-primed BMDMs treated or not with 1 µg/ml poly(dA:dT) for 4 h, 0.5 µg/ml flagellin for 4 h, or 0.1 nM Tcd B for 2 h. Cells were coimmunostained 
using antibodies against Tom20 and giantin. Nuclei were stained with DAPI. Bar, 10 µm. Data shown are representative of three independent experiments.
 o
n
 O
ctober 18, 2017
jem.rupress.org
D
ow
nloaded from
 
Protein kinase D activates the NLRP3 inflammasome | Zhang et al.2676
expressed PKD1 coimmunoprecipitated with ectopically 
expressed NLRP3 and vice versa (Fig. 8 A). Immunoblot-
ting using a PKD substrate phospho-motif antibody revealed 
phosphorylation of ectopically expressed mouse NLRP3 
in cells coexpressing constitutively active PKD1 (PKD1ca; 
Fig. 8 B). Expression of NLRP3 lacking the pyrin domain, 
the nucleotide-binding domain (NBD) or the leucine-rich 
repeat domain, respectively, revealed that phosphorylation 
occurred in the NBD (Figs. 8 B and S4 A). Expression of 
truncated and mutated NLRP3 identified phosphorylation 
of NLRP3 in the NBD at serine 293 (Ser293; Figs. 8 C and 
S4 A). Phosphorylation at Ser293 of ectopically expressed 
NLRP3 was confirmed by mass spectrometry (Fig. S4, B 
and C). This site is highly conserved among different species 
corresponding to Ser295 in human NLRP3 (Fig. S4 D). We 
next generated a phospho-Ser293–specific rabbit polyclonal 
antibody. Using this antibody, phosphorylation of ectopi-
cally expressed NLRP3 was detected in cells expressing WT 
PKD1. Expression of PKD1ca markedly enhanced phosphor-
ylation of WT, but not S293A mutant, NLRP3 (Fig. 8 D). 
Other kinases (Gross et al., 2009; Chuang et al., 2011; Lu et 
al., 2012; Martin et al., 2014; Ito et al., 2015) that have been 
implicated in NLRP3 inflammasome regulation did not in-
duce phosphorylation of NLRP3 at Ser293 (Fig. S4 E). We 
next aimed at corroborating phosphorylation of endogenous 
NLRP3. Activation of NLRP3 inflammasome by ATP and 
nigericin induced phosphorylation of NLRP3 at Ser293 
(Fig. 8 E). Moreover, NLRP3 foci in nigericin-stimulated 
THP-1 cells and ATP-stimulated BMDMs colocalized with 
signals specific for phospho-NLRP3 (Ser293), whereas there 
were no phospho-NLRP3 foci detectable in PKD-inhibited 
cells (Figs. 8 F and S5 A). Loss of phosphorylation of endog-
enous NLRP3 was confirmed in Raw-ASC macrophages 
lacking PKD1, PKD2, and PKD3 (Fig. S5 B). Hence, these 
data indicate that PKD phosphorylates NLRP3 at Ser293. 
We next asked whether PKD-mediated phosphorylation 
controls the activation of the NLRP3 inflammasome. To 
this end, we reconstituted NLRP3-deficient THP-1 cells 
with WT-, nonphospho (S293A)–, and phospho-mimicking 
(S293E) NLRP3. Reconstitution with WT NLRP3 par-
tially restored NLRP3 inflammasome activity, as indicated by 
cleavage and secretion of caspase-1 and IL-1β. In comparison, 
the capacity of S293A NLRP3 to restore inflammasome ac-
tivity was markedly lower (Fig. 8, G and H). Reconstituted 
WT NLRP3 formed foci in ∼13% of cells, whereas S293A 
NLRP3 formed foci only in ∼5% of cells. Importantly, 
S293A NLRP3 was retained in the Golgi region in ∼17% 
cells (Fig. 8, I and J), in line with retention of endogenous 
WT NLRP3 at MAMs close to the Golgi in cells subjected 
to PKD inhibition. Together with our finding that phosphor-
ylated NLRP3 can be found in the mature inflammasome, 
our data strongly suggest that PKD-mediated phosphoryla-
Figure 3. disruption of Golgi integrity 
blocks the nLrP3 inflammasome activa-
tion. (A) Immunoblotting of culture superna-
tants (Sup) and lysates (Lys) from LPS-primed 
BMDMs pretreated with ethanol (control) or 1 
µg/ml, 5 µg/ml, or 25 µg/ml BFA for 1 h, fol-
lowed by 7.5  µM nigericin treatment for 40 
min in the presence of ethanol or BFA at the 
indicated concentration. Antibodies against 
caspase-1 (recognizing both cleaved [p20] and 
uncleaved protein) and IL-1β (recognizing both 
cleaved and uncleaved protein) were used. Tu-
bulin was used as a loading control. (B) ELI SA 
measurements of IL-1β in culture supernatants 
from LPS-primed BMDMs treated as in A. The 
values are expressed as means ± SEM. ***, P < 
0.001 (t test); n.s., not significant. (C) Confocal 
fluorescence imaging of LPS-primed BMDMs 
pretreated with ethanol or 5 µg/ml BFA for 1 h, 
followed by 7.5 µM nigericin treatment for 40 
min in the presence of ethanol or 5 µg/ml BFA. 
Cells were coimmunostained with antibodies 
against ASC and giantin. Nuclei were stained 
with DAPI. Bars: 10 µm; (ROI) 2 µm. Arrow-
heads indicate the ASC foci. (D) Quantification 
of cells containing ASC foci shown in C. ***, P < 
0.001 (t test). Data shown are representative of 
three independent experiments.
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Figure 4. deficiency of PKd specifically blocks the activation of the nLrP3 inflammasome. (A) Immunoblotting of culture supernatants (Sup) and 
lysates (Lys) from LPS-primed BMDMs pretreated with DMSO, 5 µM Gö 6983, 10 µM CRT 0066101, 5 µM Gö 6976, 30 µM CID 755673, or 50 µM 2-APB for 
1 h, followed by ATP treatment for 40 min in the presence of DMSO or indicated inhibitors. l.e., long exposure; s.e., short exposure. (B) ELI SA measurements 
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tion of NLRP3 releases NLRP3 from MAMs, allowing for 
inflammasome maturation.
It has been demonstrated that binding of NLRP3 to 
MAMs is crucial for its activation (Zhou et al., 2011; Subra-
manian et al., 2013). Constitutive phosphorylation of NLRP3 
is thus expected to prevent its binding to MAMs and thus in-
flammasome activation. Indeed, expression of S293E NLRP3 
did not restore inflammasome activity in NLRP3-deficient 
THP-1 cells (Fig. 8, G and H). Moreover, S293E NLRP3 
did not form any foci localizing diffusely throughout the 
cytoplasm, which is in line with its inability to bind to 
MAMs (Fig. 8, I and J).
Our data are thus consistent with a model in which local 
and timely phosphorylation of membrane-bound NLRP3 by 
PKD results in its release and cytoplasmic assembly of the 
fully active inflammasome.
PKd activity at Golgi is sufficient to 
activate the nLrP3 inflammasome
As shown in Fig. 1, DAG production was enhanced at the 
Golgi to recruit PKD to this organelle upon NLRP3 in-
flammasome activation. Hence, PKD activity at the Golgi 
is expected to be sufficient to phosphorylate NLRP3 and 
to activate the NLRP3 inflammasome. Indeed, expression 
of WT, but not kinase-dead, PKD1 induced NLRP3 in-
flammasome-dependent activation of caspase-1 and secre-
tion of IL-1β without stimulation (Fig. 9 A). Consistently, 
expression of PKD1 dramatically enhanced the activa-
tion of caspase-1 and secretion of IL-1β upon nigericin 
treatment. Importantly, this effect was abolished by CRT 
0066101 treatment, corroborating the importance of PKD 
activity for NLRP3 inflammasome activation in inhibi-
tor experiments (Fig. 9 B). Strikingly, expression of GRIP 
tagged-PKD1, localization of which was restricted to the 
Golgi, but not of PKD lacking the DAG-binding domain, 
was sufficient to phosphorylate NLRP3 and to activate the 
NLRP3 inflammasome (Fig. 9, C and D). These data thus 
suggest that PKD activity at the Golgi is sufficient to acti-
vate the NLRP3 inflammasome.
PKd inhibition blocks the activity of the nLrP3 
inflammasome in cells from patients with 
autoactivatory mutations in nLrP3
Patients with cryopyrin-associated periodic syndrome (CAPS) 
suffer from autoinflammatory events caused by mutations in 
NLRP3 resulting in its auto-oligomerization and uncon-
trolled NLRP3 inflammasome activation (Aksentijevich et 
al., 2007; Brydges et al., 2009; Nakamura et al., 2012). We 
next determined whether autoactivation of mutated NLRP3 
inflammasome depends on PKD activity. PKD inhibition of 
LPS-stimulated PBMCs isolated from patients carrying the 
mutations T436N or R260W in the NLRP3 gene resulted 
in a strong reduction of caspase-1 cleavage and IL-1β secre-
tion as compared with control-treated cells (Fig. 10, A and 
B). T436N NLRP3 was stuck in disc-like structures at the 
Golgi upon PKD inhibition (Fig.  10  C). These mutations 
result in spontaneous self-oligomerization of the NLRP3 
protein (Baroja-Mazo et al., 2014). These data thus cor-
roborate that PKD inhibition is sufficient to block inflam-
masome activity in cells of these patients. They also indicate 
that PKD acts downstream of NLRP3 self-oligomerization. 
Indeed, a native page as well as a gel filtration assay revealed 
that PKD inhibition did not affect self-oligomerization of 
NLRP3 (Fig. S5, C and D). Given the fact that NLRP3 was 
retained at MAMs upon PKD inhibition, it is expected that 
NLRP3 at MAMs is self-oligomerized before its phosphor-
ylation. Accordingly, oligomerization of reconstituted S293E 
NLRP3 was abolished, whereas oligomerization of reconsti-
tuted S293A and WT NLRP3 were unaffected in stimulated 
THP-1 cells (Fig. S5 E).
Altogether, we propose a model in which MAMs local-
ize close to the Golgi in response to NLRP3 inflammasome 
activation. This allows for PKD-induced phosphorylation of 
self-oligomerized NLRP3, its release from MAMs, and as-
sembly of the cytosolic mature inflammasome (Fig. 10 D).
dIscussIon
In this study, we unveiled the spatial and temporal organi-
zation of NRLP3 inflammasome activation. PKD-mediated 
of IL-1β in culture supernatants from LPS-primed BMDMs treated as in A. The values are expressed as means ± SEM. p-values were calculated between ATP 
alone–treated group and ATP plus inhibitor–treated group. ***, P < 0.001 (t test); N.D., not detected; n.s., not significant. (C) Immunoblotting of culture su-
pernatants (Sup) and lysates (Lys) from LPS-primed PBMCs pretreated with DMSO or 10 µM CRT 0066101 for 1 h, followed by treatment with 5 mM ATP for 
40 min, 15 µM nigericin for 40 min, 250 or 500 µg/ml alum for 6 h, or 125 or 250 µg/ml nano-SiO2 for 6 h in the presence of DMSO or 10 µM CRT 0066101. 
(D–F) Immunoblotting of culture supernatants (Sup) and lysates (Lys) from BMDMs isolated from LysM-Cre–negative floxed PKD1-PKD3 (PKD1-PKD3fl/fl) 
control mice and LysM-Cre–positive myeloid-specific PKD1-PKD3 double-KO (PKD1-PKD3Δmy) mice. Cells were primed with LPS for 4 h. After pretreatment 
with DMSO or CRT 0066101 for 1 h, cells were stimulated with ATP for 40 min (D), alum (E), or nano-SiO2 (F) as indicated for 6 h in the presence of DMSO 
or 10 µM CRT 0066101. (G) Immunoblotting of culture supernatants (Sup) and lysates (Lys) from BMDMs isolated from PKD1-PKD3fl/fl control mice and 
PKD1-PKD3Δmy mice. Cells were transfected with control siRNA (siControl) or siRNA against PKD2 (siPKD2) as indicated for 36 h. After LPS priming for 4 h, 
cells were treated or not with 5 mM ATP or 7.5 µM nigericin for 40 min. (H) Quantitative PCR analysis of BMDMs isolated from PKD1-PKD3fl/fl control mice 
and PKD1-PKD3Δmy mice were transfected with control siRNA (siControl) or siRNA against PKD2 (siPKD2) as indicated for 36 h. The level of PKD2 mRNA 
relative to Hprt mRNA was analyzed by quantitative PCR. The values are expressed as means ± SEM. **, P < 0.01 (t test). (I) Immunoblotting of culture 
supernatants (Sup) and lysates together with culture supernatants (Lys + Sup) from Raw-ASC WT, Caspase-1–KO (Casp1 ko), NLRP3-KO (NLRP3 ko), GSD 
MD-KO (GSD MD ko), and PKD1/PKD2/PKD3 triple-KO (PKD1/2/3 ko) cells. LPS-primed cells were treated with or without 10 µM nigericin for 1 h. Asterisk (*) 
represents unspecific bands. Data shown are representative of at least three independent experiments.
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Figure 5. PKd activity is required for nLrP3 inflammasome activation in vivo. (A) Immunoblotting of culture supernatants (Sup) and lysates (Lys) 
from BMDMs isolated from PKD1-PKD3fl/fl control mice, PKD1-PKD3Δmy mice, and NLRP3-KO mice. LPS-primed cells were infected with E. coli DH5α or S. au-
reus at indicated multiplicity of infection (MOI) for 3 h. (B) ELI SA analysis of serum IL-1β from LPS-injected mice. Mice were intraperitoneally pretreated with 
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signaling emanating from the Golgi close to MAMs leads to 
phosphorylation of NLRP3 releasing it from MAMs, a neces-
sary step to allow for assembly of the mature NLRP3 inflam-
masome in the cytoplasm (Fig. 10 D).
We identified the Golgi as an important element 
controlling the activation of the NLRP3 inflammasome 
in macrophages. The importance of Golgi function is 
reflected by our observation that mitochondria cluster 
close to Golgi membranes upon inflammasome activation 
(Fig. 2), and that disruption of Golgi integrity blocks the 
activation of NLRP3 inflammasome (Fig.  3). In partic-
ular, disruption of Golgi by BFA blocked the activation 
of NLRP3 inflammasome and secretion of IL-1β. Rubar-
telli et al. (1990) showed that IL-1β was secreted via a 
BFA-insensitive pathway in LPS-activated monocytes. 
In this study, the release of IL-1β was tested in response 
to LPS stimulation only. Importantly, other studies have 
clearly demonstrated that ultrapure LPS could not trigger 
IL-1β release (Martinon et al., 2004, 2006). Thus, a plau-
sible explanation is that the release of IL-1β triggered by 
LPS in this study was induced through activation of other 
inflammasomes by contaminants. Given the fact that PKD 
activity is not important in the activation of other inflam-
masomes, their readouts were most likely independent of 
Golgi-derived signaling. A more recent study by Menu et 
al. (2012) showed that ER stress was sufficient to activate 
the NLRP3 inflammasome in LPS-primed macrophages 
without inflammasome stimulators. Different compounds, 
including BFA, were used to promote ER stress through 
different mechanisms. ER stress induced by tunicamycin 
and thapsigargin, but not BFA, was sufficient to trigger 
NLRP3 inflammasome activity in LPS-primed BMDMs. 
This is in line with our study demonstrating that BFA, 
despite its effects on ER stress, blocks the activation of 
NLRP3 inflammasome by disrupting Golgi integrity.
The importance of Golgi function is further substan-
tiated in our study at the molecular level. In fact, the sec-
ond messenger, DAG, increased in Golgi membranes (Fig. 1), 
triggering local activity of the effector kinase PKD that is 
necessary to activate the NLRP3 inflammasome (Figs. 4 and 
5). Importantly, forced targeting of PKD activity to the Golgi 
is sufficient to activate the NLRP3 inflammasome (Fig. 9). 
Finally, PKD inhibition resulted in retention of NLRP3 at 
MAMs close to Golgi membranes (Fig.  7), corroborating 
propagation of signals from the Golgi to MAMs.
Of note, PKD is a stress kinase that senses effectors of 
injured mitochondria (Storz et al., 2005). Hence, in addition 
to DAG enrichment in the Golgi, clustering of injured mi-
tochondria close to the Golgi may boost PKD activation, 
leading to phosphorylation of NLRP3 and its release from 
MAMs. Conversely, local exposure of NLRP3 with mito-
chondrial effectors may also contribute to inflammasome 
activation. It is likely that other molecular events occur at 
the interface of Golgi and MAMs that contribute to NLRP3 
inflammasome activation. In particular, the identified or-
ganelle interplay might also be crucial to couple activation 
of NLRP3 inflammasome to IL-1β secretion. In fact, signal 
propagation from the Golgi to the ER mediates formation 
of secretory autophagosomes that have been implicated in 
nonconventional secretion of IL-1β (Ponpuak et al., 2015). 
Thus, our discovery will open a whole new avenue of in-
teresting future research.
The importance of binding of NLRP3 to MAMs, even 
though it has been evidenced in the literature (Zhou et al., 
2011; Yang et al., 2015), has been challenged, because the ma-
ture NLRP3 inflammasome resides in the cytosol. In fact, our 
study integrates both observations into one coherent model 
highlighting the importance of the highly dynamic spatial 
arrangement of intracellular organelles and localization of 
NLRP3. Membrane binding of NLRP3 is dependent on the 
N-terminal sequence of its pyrin domain (Subramanian et al., 
2013). The pyrin domain is essential for NLRP3 to bind ASC 
(Dowds et al., 2003; Agostini et al., 2004). Thus, exposure of 
the pyrin domain might be essential for further maturation of 
the NLRP3 inflammasome. Importantly, the study by Zhou 
et al. (2011) demonstrated that both NLRP3 and ASC were 
found in MAM fractions, potentially indicating that interac-
tion already occurred in the MAM compartment. However, 
this study also showed that most ASC was cytoplasmic under 
both nonstimulating and stimulating conditions. We thus pro-
pose that NLRP3, without or with ASC, might be released 
from MAMs to recruit ASC or more ASC in the cytoplasm, 
forming the mature inflammasome. The detailed mechanisms 
of phosphorylation-mediated release of NLRP3 from MAMs 
will be an important subject of future research. Even though 
speculative, phosphorylation in the NBD may change con-
DMSO or 10 mg/kg CRT 0066101 as indicated for 1 h, followed by intraperitoneal injection of 20 mg/kg LPS. Blood were collected at 2 h after LPS injection. 
The values are expressed as means ± SEM. **, P < 0.01; ***, P < 0.001; n.s., not significant (Mann–Whitney test). (C) The survival curve of S. aureus–infected 
mice. WT mice were intraperitoneally pretreated with DMSO (n = 15) or 10 mg/kg CRT 0066101 (n = 15) for 1 h, followed by intraperitoneal infection of 
S. aureus (7 × 108 per mouse). **, P < 0.01 (Gehan–Breslow–Wilcoxon test). (D–F) Analysis of S. aureus–infected mice shown in C. Body temperature (D) 
and bacterial load (E and F) of each mouse was measured at 6 h after infection. The bacterial loads were shown in percentage of luminescence at 0 h. The 
values are expressed as means ± SEM. *, P < 0.05; **, P < 0.01 (Mann–Whitney test). (G) The survival curve of S. aureus–infected PKD1-PKD3fl/fl mice (n = 8) 
and PKD1-PKD3Δmy (n = 7) mice. Mice were treated by i.p. infection of S. aureus (7 × 108 per mouse). *, P < 0.05 (Gehan–Breslow–Wilcoxon test). (H) Body 
temperature of mice shown in G at 6 h after infection. The values are expressed as means ± SEM. *, P < 0.05 (Mann–Whitney test). Data shown in A are the 
representative of three independent experiments, whereas images in D are representative of 15 mice in each group.
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formation of NLRP3 in a way it prevents membrane binding. 
Alternatively, chaperone-mediated release of phosphorylated 
NLRP3 might be important.
Recently, two studies showed that PKA negatively reg-
ulates NLRP3 inflammasome activation by phosphorylation 
of NLRP3 at the very same serine residue (Guo et al., 2016; 
Mortimer et al., 2016). In fact, inhibitory effects of this phos-
phorylation event is fully in line with our observation that 
S293E NLRP3 was unable to restore inflammasome activity 
in NLRP3-deficient THP-1 cells. However, our data also pro-
vide strong evidence for PKD-mediated phosphorylation of 
NLRP3 to promote inflammasome activity. Taking all these 
findings together, this strongly suggests that the consequences 
of NLRP3 phosphorylation very likely depend on where 
Figure 6. deficiency of PKd blocks recruitment 
of Asc to the nLrP3 inflammasome. (A) Fluo-
rescence imaging of LPS-primed BMDMs pretreated 
with DMSO or 10 µM CRT 0066101 for 1 h, followed 
by stimulation with 5 mM ATP in presence of DMSO 
or 10 µM CRT for 20 min. Cells were immunostained 
with an anti-ASC antibody. Nuclei were stained with 
DAPI. Bar, 10 µm. Merged pictures with bright-field 
(BF) microscopy signals are shown. Arrowheads indi-
cate the ASC specks. (B) Quantification of ASC speck–
containing BMDMs of experiments represented in A. 
The values are expressed as means ± SEM. ***, P < 
0.001 (t test). (C) Fluorescence imaging of differen-
tiated THP-1 cells pretreated with DMSO or 10  µM 
CRT 0066101 for 1  h, followed by stimulation with 
15 µM nigericin in presence of DMSO or 10 µM CRT 
for 30 min. Cells were immunostained with an an-
ti-ASC antibody. Nuclei were stained with DAPI. Bar, 
50 µm. Arrowheads indicate ASC specks. (D) Quanti-
fication of ASC speck–containing THP-1 cells of ex-
periments represented in C. The values are expressed 
as means ± SEM. ***, P < 0.001 (t test). (E) Immuno-
blotting of culture supernatants (Sup), lysates (Lys), 
and cross-linked pellets (Pellet) from differentiated 
THP-1 cells pretreated with DMSO, 10  µM CRT, or 
25 µM BAP TA-AM for 1 h, followed by treatment with 
15 µM nigericin in presence of DMSO, 10 µM CRT, or 
25  µM BAP TA-AM for 40 min. (F) Quantification of 
ASC speck–containing LPS-primed BMDMs isolated 
from PKD1-PKD3fl/fl and PKD1-PKD3Δmy mice. Cells 
were treated with 2.5  mM ATP or 7.5  µM nigericin 
for 20 min. The values are expressed as means ± SEM. 
***, P < 0.001 (t test). Data shown are representative 
of at least three independent experiments.
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Figure 7. PKd inhibition results in nLrP3 retention at MAMs close to Golgi. (A) Confocal fluorescence imaging of PMA-differentiated THP-1 cells 
pretreated with DMSO or 10 µM CRT for 1 h, followed by stimulation with 15 µM nigericin in the presence of DMSO or CRT for 30 min. Cells were coim-
munostained with anti-NLRP3 and anti-ASC antibodies. PMA-differentiated NLRP3-KO THP-1 cells treated with nigericin and CRT was used as a negative 
control for anti-NLRP3 antibody immunostaining. Nuclei were stained with DAPI. Regions of interest (ROIs) are indicated by boxes. Bars: 10 µm; (ROI) 2 µm. 
Arrowheads indicate small NLRP3 foci; arrows indicate NLRP3 disc-like structures. (B) Quantification of cells containing small foci or disc-like structures 
in experiments represented in A. The values are expressed as means ± SEM. ***, P < 0.001 (t test); N.D., not detected. (C) Confocal fluorescence imaging of 
THP-1 cells pretreated with DMSO or 10 µM CRT for 1 h, followed by stimulation with 15 µM nigericin in the presence of DMSO or CRT for 30 min. Cells 
were coimmunostained with antibodies against NLRP3 and GM130. Nuclei were stained with DAPI. ROIs are indicated by boxes. Bars: 10 µm; (ROI) 2 µm. The 
arrowhead indicates a NLRP3 small focus, whereas the arrow indicates NLRP3 distributed in a disc-like structure. (D) 3D-SIM superresolution microscopy 
of differentiated THP-1 cells pretreated with 10 µM CRT for 1 h, followed by stimulation with 15 µM nigericin in the presence of 10 µM CRT for 30 min. 
Cells were coimmunostained with antibodies against NLRP3 and GM130. Nuclei were stained with DAPI. ROIs are indicated by boxes. Bars: 10 µm; (ROI) 
2 µm. (E) Immunoblotting of lysates from indicated fractionations (Mc, crude mitochondria; Mp, pure mitochondria) isolated from THP-1 cells pretreated 
with DMSO or 10 µM CRT for 1 h, followed by stimulation with 15 µM nigericin (Ni) in the presence of DMSO or CRT (Ni + CRT) for 30 min. Data shown are 
representative of at least three independent experiments.
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Figure 8. PKd phosphorylates nLrP3 at ser293 (in mouse, ser295 in human) to release it from MAMs. (A) Coimmunoprecipitation of exoge-
nous FLAG-tagged NLRP3 with HA-tagged PKD1 and vice versa in HEK293t cells. (B) Coimmunoprecipitation of exogenous FLAG-tagged WT (WT) NLRP3, 
NLRP3 lacking the pyrin domain (ΔPyrin), NLRP3 lacking the nucleotide-binding domain (ΔNBD), or NLRP3 lacking the leucine-rich repeats (ΔLRR) with 
GFP-tagged constitutively active mutant (ca) PKD1 in HEK293t cells. Asterisk (*) represents a band corresponding to autophosphorylation of GFP-tagged 
PKD1. (C) Coimmunoprecipitation of exogenous FLAG-tagged WT NLRP3, ΔNBD f1, ΔNBD f2, ΔNBD f3, S219A, T231A, S263;T6;9;76A (S263A; T266A; T269A; 
T276A), S293A, T318A, or S331;332A (S331A; S333A) NLRP3 with GFP-tagged constitutively active mutant (ca) PKD1 in HEK293t cells. Asterisk (*) represents 
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and when this modification occurs. In fact, phosphorylation 
of NLRP3 monomers by PKA may prevent its binding to 
MAMs, inhibiting inflammasome assembly. Local phosphory-
lation of self-oligomerized NLRP3 by PKD, however, releases 
it from MAMs, allowing for assembly of the mature inflam-
masome. It is possible, however, that other phosphorylation 
events mediated by other kinases or other posttranslational 
modifications downstream of PKD-mediated phosphory-
lation control inflammasome activation. Importantly, a very 
recent study showed that both nonphospho- and phospho-
mimetic mutants of NRLP3 at serine 5 (Ser5) are inhibitory 
(Stutz et al., 2017), very similar to the observations we made 
with NLRP3 mutants at Ser293. Interestingly, it has been 
previously demonstrated that N-terminal amino acid residues 
from 2 to 9 are required for binding to membranes (Subrama-
nian et al., 2013). We thus speculate that phosphorylation of 
Ser5, which may occur downstream of PKD-mediated phos-
phorylation, prevents membrane binding of NLRP3.
Other kinases, including Syk, JNK, PKR, DAPK, BTK, 
and IKKα, have been implicated in the activation of the 
NRLP3 inflammasome (Jo et al., 2016). We demonstrated 
that none of these kinases was capable to phosphory-
late NLRP3 at Ser293 (Fig. S4 E). These data are in line 
with the fact that none of these kinases have been shown 
to phosphorylate NLRP3, nor did their inactivation result 
in specific phenotypes we describe in this study, in partic-
ular retention of NLRP3 in the Golgi–MAM compart-
ment. Most recently, the kinase NEK7 has been discovered 
to mediate oligomerization of NLRP3, whereas its cata-
lytic activity was shown to be redundant in this context 
(He et al., 2016; Shi et al., 2016). Our data are in line with 
these findings as PKD most likely phosphorylates NLRP3 
downstream of its self-oligomerization and releases it from 
MAMs, allowing the assembly of mature inflammasome 
in cytosol (Fig. 10 D).
We also demonstrated that enrichment of DAG in 
Golgi membranes was PLC dependent (Fig.  1). Accord-
ingly, PKD activity is dependent on PLC-mediated DAG 
production (Rozengurt et al., 2005). Our findings are fully 
in line with studies revealing that pharmacological inhibi-
tion of PLC blocked the activation of the NLPR3 inflam-
masome, whereas a PLC agonist was sufficient to activate 
the latter (Lee et al., 2012; Murakami et al., 2012). Acti-
vation of PLC by G protein–coupled receptor signaling at 
the plasma membrane was shown to be insufficient to ac-
tivate the NLRP3 inflammasome (Katsnelson et al., 2015). 
However, the involvement of other PLC isoforms, which 
are activated through G protein–independent pathways 
(Rhee, 2001), has not been investigated. Alternatively, PLC 
directly at the Golgi could be critical for PKD-mediated 
NLRP3 inflammasome activation (Fig.  10  D). In fact, 
PLC-mediated generation of DAG from phosphoinosit-
ides in the Golgi complex has been reported. Both the 
substrates and PLC of this pathway are present in this 
organelle (Barker et al., 1998; Jin et al., 2001). Of note, 
gain-of-function mutations in phospholipase C γ2 lead to 
dominantly inherited autoinflammatory diseases (Yu et al., 
2005; Everett et al., 2009; Abe et al., 2011; Ombrello et al., 
2012; Koss et al., 2014). Patients carrying a gain of function 
in phospholipase C γ2 showed enhanced IL-1β produc-
tion due to hyperactivation of the NLRP3 inflammasome, 
highlighting the importance of PLC-mediated signaling in 
the context of NLRP3 inflammasome activation (Zhou et 
al., 2012; Chae et al., 2015).
Several research teams have reported that Ca2+ mobi-
lization plays an important role in NLRP3 inflammasome 
activation (Horng, 2014). Recently however, it has been sug-
gested that intracellular Ca2+ signaling is neither necessary 
nor sufficient to activate the NLRP3 inflammasome (Kats-
nelson et al., 2015). Our model implements PLC-dependent 
local exchange of Ca2+ at MAMs that has not been moni-
tored in the latter study. Furthermore, we found that another 
effect of PLC activation, DAG-mediated PKD signaling from 
the Golgi, was critical to release NLRP3 from MAMs allow-
ing for full inflammasome maturation. This may explain why 
mobilization of Ca2+ by some stimuli is insufficient to activate 
the NLRP3 inflammasome.
Altogether, our work thus uncovered a fundamentally 
new organelle interplay to be at the basis of cellular innate 
immune responses. Finally, we propose that interference with 
this signaling mechanism might be a promising avenue to treat 
NLRP3-related inflammatory disorders, including CAPS.
a band corresponding to autophosphorylation of GFP-tagged PKD1. (D) Immunoblotting of lysates from HEK293t cells ectopically expressing FLAG-tagged 
WT or S293A mutant NLRP3 together with GFP-tagged WT or ca PKD1. (E) Immunoprecipitation of endogenous NLRP3 in BMDMs isolated from WT and NL-
RP3-KO mice. LPS-primed BMDMs were treated with or without 5 mM ATP or 7.5 µM nigericin as indicated for 30 min. Asterisk (*) represents an unspecific 
band. (F) Confocal fluorescence imaging of differentiated THP-1 cells pretreated with DMSO or 10 µM CRT 0066101 for 1 h, followed by 15 µM nigericin 
treatment in the presence of DMSO or 10 µM CRT 0066101 for 30 min. Cells were coimmunostained with antibodies against NLRP3 and p-NLRP3 (Ser293). 
Nuclei were stained with DAPI. Bar, 10 µm. The arrowhead indicates a small NLRP3 focus colocalizing with p-NLRP3 signal, whereas the arrow indicates 
NLRP3 distributed in a disc-like structure lacking the p-NLRP3 signal. (G) Immunoblotting of culture supernatants (Sup) and lysates (Lys) from WT and NL-
RP3-KO THP-1 cells reconstituted with empty vector (e.v.), WT, S293A, or S293E mutant NLRP3. PMA-differentiated cells were treated with 15 µM nigericin 
for 30 min. (H) ELI SA measurements of IL-1β in culture supernatants from cells treated as in G. The values are expressed as means ± SEM. ***, P < 0.001 (t 
test). (I) Confocal fluorescence imaging of NLRP3-KO THP-1 cells reconstituted with WT, S293A, or S293E mutant NLRP3. Cells were coimmunostained with 
antibodies against NLRP3 and GM130. Nuclei were stained with DAPI. Bar, 10 µm. The arrowhead indicates a small NLRP3 focus, whereas the arrow indicates 
NLRP3 distributed in a disc-like structure. (J) Quantification of cells containing small foci or disc-like structures in experiments represented in I. The values 
are expressed as means ± SEM. **, P < 0.01; ***, P < 0.001 (t test). N.D., not detected. Data shown are representative of three independent experiments.
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MAterIALs And MetHods
Mice
NLRP3−/− mice on C57BL/6J background were obtained 
from The Jackson Laboratory. Mice with targeted alleles for 
PKD1 (PKD1fl/fl) were described previously (Fielitz et al., 
2008). PKD1 floxed (PKD1fl/fl) mice were provided by R. 
Bassel-Duby and E.N. Olson (University of Texas Southwest-
ern, Dallas, TX). Generation of PKD3 floxed mice have been 
previously described (Zhang et al., 2016). We crossed PKD1fl/fl 
mice and PKD3fl/fl mice on C57BL/6J background with 
Lys M-Cre mice to obtain myeloid-specific PKD1-PKD3 
double-KO mice. C57BL/6J WT mice were ordered from 
Charles River Laboratories. Mice were housed under spe-
cific pathogen–free conditions. All animal experimentation 
was approved by the Direction des Services Vétérinaires du 
Bas-Rhin, France, except that bacteria infection experiments 
were approved by Comité Régional d’Ethique en Matière 
d’Expérimentation Animale de Strasbourg (CRE MEAS). 
Figure 9. PKd activity at the Golgi is required and sufficient to activate the nLrP3 inflammasome. (A) Immunoblotting of culture supernatants 
(Sup) and lysates (Lys) from THP-1 WT and NLRP3-KO cells infected with lentiviruses as indicated. Cells were treated with 100 nM PMA for 3 h, followed by 
replacement of fresh medium for 12 h. e.v., empty vector. (B) Immunoblotting of culture supernatants (Sup) and lysates (Lys) from THP-1 NLRP3-KO cells 
infected with lentiviruses as indicated. PMA-differentiated cells were pretreated with DMSO or 10 µM CRT 0066101 for 1 h, followed by 15 µM nigericin 
treatment in the presence of DMSO or 10 µM CRT 0066101 for 30 min. e.v., empty vector. (C and D) Immunoblotting of culture supernatants (Sup) and 
lysates (Lys) from stable THP-1 cell lines ectopically expressing GFP, GFP-tagged PKD1 WT, or a PKD1 mutant without the cysteine-rich domain (ΔCRD; C), 
GFP-GRIP-tagged WT, constitutively active (ca), or KD PKD1 (D). Cells were treated with 100 nM PMA for 3 h, followed by replacement of fresh medium for 
12 h. Asterisk (*) represents an unspecific band. Data shown are representative of three independent experiments.
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Figure 10. PKd activity is required for activation of the 
nLrP3 inflammasome in cells from cAPs patients. (A and B) 
Immunoblotting of culture supernatants (Sup) and lysates (Lys) 
from PBMCs isolated from CAPS patients carrying the NLRP3 
T436N mutation (A) or the R260W mutation (B). Cells were left 
untreated or treated with 1 µg/ml LPS in the presence of DMSO 
or CRT 0066101 10 µM for 4 h. (C) Confocal fluorescence imaging 
of PBMCs isolated from CAPS patients carrying the NLRP3 T436N 
mutation were left untreated or treated with 1 µg/ml LPS in the 
presence of DMSO or 10 µM CRT 0066101 for 4 h. Cells were co-
immunostained with antibodies against NLRP3 and ASC. Nuclei 
were stained with DAPI. Regions of interest (ROIs) are indicated 
by boxes. Bars: 10 µm; (ROI) 2 µm. (D) Model implementing iden-
tified mechanisms in the activation of the NLRP3 inflammasome. 
The dashed black ellipse highlights the interaction of the Golgi 
with the MAM. Data shown in A to C are representative of ex-
periments using PBMCs isolated from two CAPS patients car-
rying the same mutation.
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No exclusion of animals used for experiments was per-
formed. Healthy mouse littermates were chosen randomly 
according to their genotypes.
reagents
Nigericin sodium salt (catalog no. N7143), BFA (B7651), 
ATP (A2383), and LPS from E. coli 055:B5 (L2880) were 
purchased from Sigma-Aldrich. CRT 0066101 (4975), kb 
ND 142–70 (3962), 2-APB (1124), BAP TA-AM (2787), 
U73122 (1268), CID 755673 (3327), Gö 6976 (2253), and 
Gö 6983 (2285) were purchased from Tocris Bioscience. Na-
no-SiO2 (tlrl-sio) and flagellin from Salmonella typhimurium 
(tlrl-stfla) were obtained from InvivoGen. Alum (77161) was 
purchased from Thermo Fisher Scientific.
Plasmids
Mouse NLRP3 was amplified from cDNA by PCR. NLRP3 
wt and NLRP3 mutants were cloned into pBOB, pLV, or 
pEGFP-N1 empty vectors using ligation-independent clon-
ing (LIC). Rat PKCδ C2 (DAG-binding domain), which was 
amplified from GFP-C1(2) delta (plasmid #21216; Addgene), 
human PKD1 wt, and PKD1 ΔCRD were cloned to pBOB 
empty vector expressing C-terminal–fused EGFP tag. Golgi- 
localized PKD1 WT, constitutively active, and kinase-dead 
were cloned by a C-terminal fusion of GRIP domain of 
p230 as described previously (Kjer-Nielsen et al., 1999). 
The pX330-P2A-EGFP plasmid was generated by insert-
ing P2A-EGFP sequence into EcoRI-digested pX330-U6- 
Chimeric_BB-CBh-hSpCas9 (plasmid #42230, Addgene) 
before stop codon using LIC. Guide RNA (gRNA) se-
quences were inserted into BbsI-digested pX330-P2A-EGFP 
plasmid through ligation by T4 DNA ligase.
cell culture
All mammalian cells were cultured at 37°C, 5% CO2. Cell 
lines used in this study are not listed in these databases of com-
monly misidentified cell lines maintained by ICL AC. THP-1 
cells (ATCC) were grown in RPMI 1640 containing 10% fetal 
bovine serum, 10 mM Hepes, 2.5 g/l glucose, 1 mM sodium 
pyruvate and gentamycin. HEK293t cells (DKFZ Heidelberg) 
were grown in DMEM containing 1 g/ml glucose, 10% fetal 
bovine serum, penicillin and streptomycin. THP-1 cells and 
HEK293t cells have been authenticated using short tandem 
repeat performed by LGC Standards. BMDMs were obtained 
by differentiating bone marrow progenitors from the tibia 
and femur in RPMI 1640 containing 30% L929-conditional 
medium or 50 ng/ml recombinant hM-CSF (11343113; Im-
munotools), 20% heat-inactivated fetal bovine serum, peni-
cillin and streptomycin for 7 d. Peritoneal macrophages were 
isolated from mice by peritoneal lavage on day 4 after the 
injection of 3.7% thioglycollate medium (1 ml/mouse). Both 
BMDMs and peritoneal macrophages were seeded 1 d before 
experiments using RPMI 1640 containing 10% heat-inacti-
vated fetal bovine serum, penicillin and streptomycin. Human 
bloods from healthy control and CAPS patients (approved by 
the Institut National de la Santé et de la Recherche Médi-
cale ethics committee) were collected after the patients gave 
their signed informed consent. PBMCs were isolated using 
Ficoll-Paque PLUS (GE Healthcare) and cultured in RPMI 
1640 containing 10% heat-inactivated fetal bovine serum and 
penicillin and streptomycin. Cell cultures were negative for 
mycoplasma contamination.
To activate the NLRP3 inflammasome, BMDMs, peri-
toneal macrophages, or PBMCs were primed with 1 µg/ml 
LPS for 4 h, followed by the treatment of 2.5 mM or 5 mM 
ATP for 20 to 40 min, 7.5 µM or 15 µM nigericin for 20 
to 40 min, 250 µg/ml or 500 µg/ml alum for 6  h, or 30 
to 120 µg/ml nano-SiO2 for 6 h, whereas THP-1 cells were 
differentiated by 100 nM PMA treatment for 3 h, followed 
by overnight incubation with fresh medium before the treat-
ment of NLRP3 inflammasome activators. For the infec-
tion of BMDMs by E. coli DH5α and S. aureus (strain Xen 
8.1; Xenogen), overnight cultures of bacteria were seeded 
in LB medium by 1/100 dilution and grew until OD600 
reached 0.6 at 37°C; bacteria were collected by centrifuga-
tion and washed three times with sterile 1×PBS. LPS-primed 
BMDMs were infected at multiplicity of infection of 20 
or 50 for 3 h. For activation of AIM2- or NLRC4 inflam-
masome, LPS-primed BMDMs were transfected with 1 µg/
ml poly(dA:dT) or 0.5 µg/ml flagellin, respectively, for 4 h 
using Lipofectamine 2000 (Life Technology) according to the 
manufacturer’s protocol, whereas for activation of PYR IN 
inflammasome, LPS-primed BMDMs were treated with 0.1 
nM recombinant cytotoxin TcdB for 2 h. For inhibitors treat-
ment, the cells were pretreated with inhibitors for 1 h before 
the treatment of cognate stimuli in present of inhibitors.
For the packaging of lentivirus, 12 µg Lenti-mix (3 µg 
pVSVG, 3 µg pMDL, and 3 µg pREV) plus 12 µg of gene of 
interest expressing plasmid were transfected into HEK293t 
cells (10-cm plate) using Lipofectamine 2000. After 48  h, 
the supernatants were collected and filtered using 0.45-µm 
Millex-HV syringe filters and kept at −80°C. BMDMs and 
THP-1 cells were infected in fresh medium containing 1 
µg/ml polybrene (sc-134220; Santa Cruz) and 25% lentivi-
rus-contained supernatant.
For the knockdown of PKD2, 1.0 × 106 BMDMs were 
seed in each well of a six-well plate on the day before trans-
fection. Cells were transfected with 100 pmol ON-TAR GET 
plus Non-targeting Pool (D-001810-10-05; Dharmacon) or 
ON-TAR GET plus Mouse PKD2 (101540) siRNA-SMA RT 
pool (L-040693-00-0005; Dharmacon) using DharmaFECT 
4 Transfection Reagent (T-2004-01; Dharmacon). 36  h 
after transfection, cells were collected for RNA isolation or 
treated with LPS plus ATP or nigericin for 40 min to activate 
the NLRP3 inflammasome.
Gene disruption using crI sPr/cas9 genome editing system
For generation of NLRP3 KO THP-1 cell lines, guide RNA 
(gRNA) sequence (5′-GTA CCT GGC CAG CTT GCA GC3′) 
was cloned into pX330-P2A-EGFP through ligation using 
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T4 ligase. THP-1 cells were transfected using Cell Line Nu-
cleofector kit V (VCA-1003; Lonza). 24 h after transfection, 
GFP-positive cells were enriched by FACS (BD FACS Aria 
II) and seeded into 96-well plates. Obtained NLRP3-KO 
single-cell clones were validated by immunoblotting and 
sequencing of PCR-amplified targeted fragment. The fol-
lowing primers were used for PCR amplification: 5′-AAA 
GAC TCA TCC GTG TGC CGT GTTC-3′ and 5′-TCC CCA 
TTG AAG TCG ATC ATT AGCG-3′. Raw264.7-ASC (Raw-
ASC) WT, NLRP3-KO, Caspase-1–KO, and GSD MD-KO 
cell lines were generated as described previously (He et al., 
2015). For the generation of PKD1/2/3 triple KO Raw-ASC 
cell line, three gRNAs respectively targeting PKD1 (gRNA 
sequence: 5′-CTC ATG GAT GAC ATG GACG-3′), PKD2 
(gRNA sequence: 5′-TAC ATC CCC CTG ATG CGCG-3′) 
and PKD3 (gRNA sequence: 5′-GAC CCG ACT GAT CTC 
GACG-3′) were used. Obtained PKD1/PKD2/PKD3 tri-
ple-KO single-cell clones were validated by sequencing of 
PCR-amplified targeted fragments. The following primers 
were used for PCR amplification: 5′-AGA GAA TTC GGA 
TCC CTG GTT CTA AGA GTC CGG GCT-3′ and 5′-CTT 
CCA TGG CTC GAG CTC TGG GGC AAC CAA GCT CC-3′ 
for PKD1; 5′-AGA GAA TTC GGA TCC GTG CGT GTG 
CTC CAT ATT CACA-3′ and 5′-CTT CCA TGG CTC GAG 
CTT ATG GGT CCA TGC CAA CTCA-3′ for PKD2; 5′-AG 
A GAA TTC GGA TCC GAC TGG TCT GCT TAG GTG CA 
TT-3′ and 5′-CTT CCA TGG CTC GAG CCT GAA TGG AG 
C TCC TGA CCTG-3′ for PKD3.
Measurement of mitochondrial oxygen consumption
OCRs were measured using an XF96 Extracellular Flux An-
alyzer (Seahorse Bioscience). Measurements were performed 
using assay medium (Seahorse XF base medium supple-
mented with 1  mM sodium pyruvate, 2  mM l-glutamine, 
and 10 mM glucose) according to the Seahorse XF Cell Mito 
Stress Test kit (part 103015–100; Seahorse Bioscience) user 
guide. 1.0 × 105 THP-1 WT or NLRP3-defiecnt cells were 
seed in each well in presence of 100 nM PMA. 3  h later, 
medium was replaced by fresh medium. The next day, cells 
were washed once with assay medium and equilibrated with 
assay medium containing DMSO or 10 µM CRT 0066101 at 
37°C for 1 h in an incubator without CO2. 15 µM nigericin, 
2.0 µM oligomycin, 1.0 µM FCCP, and 0.5 µM rotenone/an-
timycin were sequentially injected at 9 min, 42 min, 60 min, 
and 78 min. Mixing, waiting, and measurement times were 3, 
0, and 3 min, respectively.
Immunoprecipitation and immunoblotting
After treatments, cell supernatants and cell lysates were 
collected for immunoblotting analysis. Cell lysates were 
collected in 1× SDS sample buffer or in 1× RIPA buffer 
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 
1 mM EDTA, 1 mM EGTA, 2 mM sodium pyrophosphate, 
1 mM NaVO4, and 1 mM NaF) supplemented with prote-
ase inhibitor cocktail. The immunoblot were prepared using 
Tris-glycine SDS-PAGE. For the supernatants, the proteins 
were extracted using methanol-chloroform precipitation, 
separated by Tricine SDS-PAGE, and analyzed by immuno-
blotting. For immunoprecipitation, FLAG-tagged NLRP3 
was immunoprecipitated using anti-FLAG M2 Affinity Gel 
(A2220; Sigma-Aldrich), whereas HA-tagged PKD1 was 
done using EZview Red Anti-HA Affinity Gel (E6779; 
Sigma- Aldrich). After washing, bound proteins were eluted 
by 2× SDS sample buffer and analyzed by immunoblots for 
NLRP3 or PKD1 with anti-FLAG or anti-HA antibodies. 
For analysis of the ASC pyroptosome, pellets from whole-
cell lysates were cross-linked with disuccinimidyl suberate 
and analyzed by immunoblotting. The immunoblots were 
probed overnight at 4°C or 1 h at room temperature with 
anti–human IL-1β antibody (AF-201-NA; R&D Systems), 
anti–human caspase-1 antibody (06-503; Merck Millipore), 
anti–mouse IL-1β antibody (5129-100; BioVision), anti–
mouse caspase-1 p10 antibody (sc-514; Santa Cruz Biotech-
nology), anti–mouse caspase-1 p20 (AG-20B-0042-C100; 
AdipoGen), anti-ASC antibody (sc-22514; Santa Cruz Bio-
technology), anti-NLRP3 antibody (G-20B-0014-C100; 
AdipoGen); anti-GAP DH (G9545; Sigma-Aldrich), anti- 
tubulin (T9026; Sigma-Aldrich), anti–phospho-PKD/PKCμ 
(Ser916) antibody (2051; Cell Signaling Technology), anti–
phospho-(Ser/Thr) PKD substrate antibody (4381; Cell Sig-
naling Technology), rabbit anti–phospho-NLRP3 (Ser295) 
antibody (homemade: serine-phosphorylated “RKPSRIL 
FLC” peptide was used for immunization of rabbits; after 
the purification using serine-phosphorylated peptide, phos-
phorylation-specific antibody was obtained through deple-
tion using nonphosphorylated peptide), anti-PKD3 antibody 
(5655; Cell Signaling Technology), anti-PKD antibody (C-20; 
sc-639; Santa Cruz Biotechnology), anti-GSD MD (20770–1-
AP; Proteintech), anti-GM130 antibody (11308-AP; Pro-
teintech), anti-calnexin antibody (10427-2-AP; Proteintech), 
anti-Tom20 antibody (sc-11415; Santa Cruz Biotechnology), 
anti-FLAG antibody (F1804; Sigma-Aldrich); and anti-HA 
antibody (sc-805; Santa Cruz Biotechnology).
Immunofluorescence microscopy
After treatments, cells plated on coverslips (9–15 mm) were 
fixed in 4% paraformaldehyde for 15 min at room tempera-
ture. Cells were permeabilized for 10 min using 0.25% Triton 
X-100 in PBS. After blocking with 10% normal goat serum 
for 1 h, cells were incubated with anti-ASC antibody (1:100 
dilution; sc-22514; Santa Cruz Biotechnology), anti-NLRP3 
antibody (1:100 dilution; G-20B-0014-C100; AdipoGen; 
previously approved for immunostaining; Man et al., 2014), 
anti–phospho-NLRP3 (Ser295) antibody (generated as de-
scribed in the methodology section Immunoprecipitaion and 
immunoblotting above; 1:50), anti-giantin antibody (1:300 di-
lution; ALX-804-600-C100; Enzo Life Science), anti- giantin 
antibody (1:300 dilution; AB24586; Abcam), anti-GM130 
antibody (1:300 dilution; 11308-AP; Proteintech), and an-
ti-Tom20 antibody (1:500 dilution; sc-11415; Santa Cruz 
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Biotechnology) for 1 h at room temperature. After incubation 
with secondary antibodies for 1 h at room temperature, cells 
were stained with DAPI and mounted. Images were acquired 
using Confocal Laser Scanning Microscope TCS SP8 (Leica).
cellular fractionation
Isolation of MAMs was performed as described previously 
(Wieckowski et al., 2009). In brief, ∼3 × 108 cells were ho-
mogenized using a 15-ml Dounce tissue grinder in buffer con-
taining 30 mM Tris-HCl, pH 7.4, 225 mM mannitol, 75 mM 
sucrose, and 0.1  mM EGTA. Homogenized cells were cen-
trifuged at 600 g for 5 min to remove nuclei and intact cells. 
Crude mitochondria pellet was collected by centrifugation at 
7,000 g for 10 min. Crude mitochondria pellet was suspended 
in ice-cold buffer containing 5  mM Hepes-KOH, pH 7.4, 
250 mM mannitol, and 0.5 mM EGTA, and layered on top 
of 8 ml Percoll medium (20%). Pure mitochondria and MAM 
fractions were separated by centrifugation at 95,000 g for 30 
min. Golgi was isolated using Golgi isolation kit (GL0010; 
Sigma- Aldrich) according to the manufacturer’s protocol.
Gel filtration assay
For each condition, cells were plated on ten 150-mm dishes, 
treated with 100 nM PMA for 3 h, and incubated overnight 
in fresh medium. The next day, cell were pretreated with 
DMSO or 10 µM CRT 0066101 for 1 h, followed by treat-
ment with 15 µM nigericin in presence of DMSO or 10 µM 
CRT 0066101 for 30 min. After the treatments, cells were 
collected in PBS. Cells were washed twice with ice-cold PBS 
and sonicated for 2 min (2 s on and 2 s off) on ice in 1× PBS 
containing 2 mM DTT. Cell lysates were clarified by cen-
trifugation, followed by filtration with 0.2 µm Minisart filter 
(Sartorius Stedim Biotech). The flow through was injected 
into Superose 6 Column (GE Healthcare) running at a flow 
rate of 0.5 ml/min. Fractions were collected by 500 µl for 
each and analyzed by immunoblotting.
Blue native PAGe
Blue native PAGE electrophoresis was performed using 
Novex NativePAGE Bis-Tris gel system (Thermo Fisher 
Scientific). In brief, 2.0 × 106 THP-1 cells after treatments 
were washed once with ice-cold 1× PBS and then lysed in 
ice-cold 1× native lysis buffer containing 1% digitonin and 
EDTA-free protease inhibitor cocktail (Roche Diagnostics) 
for 30 min on ice. Lysates were clarified by centrifugation at 
20,000 g for 30 min at 4°C before quantification using Brad-
ford protein assay (Bio-Rad). Mature inflammasomes were 
pelleted by centrifugation because of their insolubility. Equal 
amount of lysates were separated by 3–12% blue native PAGE. 
Proteins in native gels were transferred to PVDF membranes 
(Millipore), followed by conventional immunoblotting.
shotgun mass spectrometry
FLAG-tagged NLRP3 (mouse) was coexpressed with GFP 
or GFP-tagged constitutively active PKD1 in HEK293t cells. 
36 h after transfection, cells were lysed in RIPA buffer. FLAG-
tagged NLRP3 was immunoprecipitated using anti-FLAG 
M2 Affinity Gel. Immunoprecipitated samples were sepa-
rated by 8% SDS-PAGE gel (14 cm wide × 9 cm long) and 
stained with Coomassie blue. The bands covering NLRP3 
were cut and proceeded for in-gel digestion (Shevchenko et 
al., 2006) using Asp-N enzyme (Roche Diagnostics). Sam-
ples after Asp-N digestion were subjected to LC-MS/MS 
analysis by Oribtrap XL. The raw files acquired were pro-
cessed with MaxQuant software (version 1.5.2.8) according 
to the standard workflow. Database search was performed in 
MaxQuant with Andromeda search engine against the mouse 
Swiss-Prot database. The identified results together with the 
raw data were further visualized by Viewer in MaxQuant and 
analyzed by Sklyine software.
Flow cytometry
Tibia bones and spleens were isolated from PKD1-PKD3fl/
fl and PKD1-PKD3Δmy mice. Bone marrow cells were 
flushed out and spleens were homogenized with 1× PBS 
containing 1% BSA. 2 × 105 cells were used and blocked 
with antibody against CD32/16 (553141; BD Biosciences) 
for 5 min at room temperature, followed by staining with 
antibodies against CD11b (101225; BioLegend), CD11c 
(561045; BD PharMingen), CD115 (135505; BioLegend), 
Ly6c (128015; BioLegend), CD117 (105813; BioLegend), 
CX3CR1 (149009; BioLegend) for 20 min on ice in the 
dark. After washing, cells were analyzed by FACS (LSR II; 
BD). Dead cells were excluded by DAPI staining. Monocytes 
and macrophages were identified as CD11b+CD11c−Ly-
6c+CD115+ using FlowJo. Bone marrow derived monocyte/
DC progenitors were identified as CD11b−CD11c−CD115+ 
CD117+Cx3CR1+. Counts of monocytes and macrophages 
were shown as percentage of counted intact cells.
Quantitative Pcr
RNA was extracted using TRIzol reagent (Sigma-Aldrich). 
Complementary DNA was synthesized with Oligo-dT 
primer using SuperScript II First-Strand cDNA Synthe-
sis kit (Invitrogen) according to the manufacturer’s proto-
col. Quantitative PCR was performed using SYBR Green 
(Roche Diagnostics) on the LightCycler 480 (Roche Di-
agnostics). The samples were individually normalized to 
the housekeeping gene hypoxanthine-guanine phosphori-
bosyltransferase (HPRT). The following primers were used: 
Hprt forward: 5′-TCA GTC AAC GGG GGA CAT AAA-3′, 
reverse: 5′-GGG GCT GTA CTG CTT AAC CAG-3′; TNF 
forward: 5′-CAT CTT CTC AAA ATT CGA GTG ACAA-3′, 
reverse: 5′-TGG GAG TAG ACA AGG TAC AAC CC-3′; 
IL-1β forward: 5′-GCC CAT CCT CTG TGA CTC AT-3′, 
reverse: 5′-AGG CCA CAG GTA TTT TGT CG-3′; IL-6 for-
ward: 5′-GAG GAT ACC ACT CCC AAC AGA CC-3′, reverse: 
5′-AAG TGC ATC ATC GTT GTT CAT ACA-3′; IL-12p40 
forward: 5′-CCT GAA GTG TGA AGC ACC AA-3′, reverse: 
5′-AGT CCC TTT GGT CCA GTG TG-3′; and PKD2 for-
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ward: 5′-TGT GTT TTC CTC CAT AAA CC-3′, reverse: 5′-
CCA CTG TCT ACC AGA TCT TC-3′.
LPs injection and peritoneal infection of s. aureus in mice
LPS were injected into mice at a dose of 20 mg/kg. Blood 
was collected at 2 h after injection. For S. aureus infection, 
bacteria cultures in exponential growth phase were centri-
fuged and the pellet was resuspended in 1× PBS. Approx-
imately 7 × 108 CFUs of luminescent S. aureus in 200  µl 
were inoculated to each anesthetized mouse by peritoneal 
injection. Hairs were removed by chemical depilation before 
inoculation. Body temperature were measured at 6  h after 
inoculation. Luminescence was monitored immediately after 
the inoculation and at 6 h after inoculation with a CCD cam-
era using an IVIS50 system from Caliper (5 min exposure 
of the animals), and quantification was done with the Liv-
ing Image3.2 program from Xenogen/Caliper. For inhibitor 
pretreatment, 10 mg/kg CRT 0066101 was injected at 1 h 
before LPS injection or S. aureus inoculation.
Measurement of cytokines using eLI sA
Mouse IL-1β, TNF, and IL-6 in cell culture supernatants 
were measured using the MIL LIP LE MAP mouse cy-
tokines multiplex assay according to the manufacturer’s 
protocol. Human IL-1β was measured using the Quanti-
kine ELI SA Human IL-1/IL1F2 Immunoassay (DLB50; 
R&D Systems). Mouse serum IL-1β was measured using 
the Quantikine ELI SA mouse IL-1/IL1F2 Immunoas-
say (MLB00C; R&D Systems).
statistical analyses
Preliminary experiments were performed and sample 
size was determined based on generally accepted rules 
to test preliminary conclusions reaching statistical sig-
nificance, where applicable. Gehan–Breslow–Wilcoxon 
tests were performed for survival curves; Mann–Whitney 
tests were performed for serum IL-1β levels, body tem-
peratures, and bacterial loads. Statistical analyses for the 
other experiments were performed with the t test using 
Prism (GraphPad Software).
online supplemental material
Fig. S1 includes additional data related to Fig.  4, showing 
that deficiency of PKD blocks the activation of NLRP3 
inflammasome without affecting lineage development 
of mouse myeloid cells, LPS priming and secretion of 
other NF-κB-dependent cytokines. Fig. S2 includes ad-
ditional data related to Figs. 6 and 7, showing that the 
requirement of PKD activity is specific for NLRP3 in-
flammasome, but not the other inflammasomes. Fig. S3 
shows PKD acts downstream of mitochondrial clustering 
and dysfunction. Fig. S4 includes additional data related to 
Fig. 8, consolidating the phosphorylation of NLRP3 at Ser 
293 by PKD. Fig. S5 shows that PKD acts downstream of 
self-oligomerization of NLRP3.
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